Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Curr Treat Options Oncol. 2024 Mar;25(3):293-312. doi: 10.1007/s11864-023-01173-1. Epub 2024 Jan 4.
Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals of cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.
近年来，转移性激素敏感型前列腺癌的治疗方法有了重大进展，总体生存率有了显著提高。现在，男性的中位生存期几乎达到了 6 年，比以往任何时候都活得更长。转移性疾病的时间和程度以及个体患者的因素有助于推荐使用包括雄激素剥夺治疗（ADT）加化疗或雄激素受体信号抑制（ARSI）在内的双药治疗或 ADT+ARSI+化疗的三联治疗。必须继续开发新的治疗方法来提高生存率，以期治愈。更好的生物标志物将有助于更有效地治疗，从而提高疾病控制、生活质量和生存率。
